Abstract
Background Pertussis vaccines containing three or five pertussis antigens are recommended in pregnancy in many countries, but no studies have compared the effect on infants’ antigen-specific immunoglobulin G (IgG) concentrations. The aim of this study was to compare anti-pertussis IgG responses following primary immunization in infants of mothers vaccinated with TdaP5-IPV (low dose diphtheria toxoid, tetanus toxoid, acellular pertussis [five antigens] and inactivated polio) or TdaP3-IPV in pregnancy (three pertussis antigens).
Methods This multi-centre phase IV randomized clinical trial was conducted in a tertiary referral centre and primary care sites in England from 2014-2016. Women were randomized to receive TdaP5-IPV (n=77) or TdaP3-IPV (n=77) at 28-32 gestational weeks. A non-randomized control group of 44 women who had not received a pertussis-containing vaccine in pregnancy and their 47 infants were enrolled postpartum.
Results Following infant primary immunization, there was no difference in the geometric mean concentrations (GMCs) of anti-pertussis toxin, filamentous haemagglutinin or pertactin IgG between infants born to women vaccinated with TdaP5-IPV (n=67) or TdaP3-IPV (n=63). However, the GMC of anti-pertussis toxin IgG was lower in infants born to TdaP5-IPV and TdaP3-IPV vaccinated mothers compared to infants born to unvaccinated mothers (n=45) (geometric mean ratio: 0.71 [0.56-0.90] and 0.78 [0.61-0.98], respectively); by 13 months of age, this difference was no longer observed.
Conclusion Blunting of anti-pertussis toxin IgG response following primary immunization occurs in infants born to women vaccinated with TdaP5-IPV and TdaP3-IPV, with no difference between maternal vaccines. The blunting effect had resolved by 13 months of age. These results may be helpful for countries considering which pertussis-containing vaccine to recommend for use in pregnancy.
Clinical Trials identifier ClinicalTrials.gov: NCT02145624
Competing Interest Statement
CEJ, AC, AK, PTH have conducted studies on behalf of St Georges, University of London and the University of Southampton and University Hospital Southampton NHS Foundation Trust (CEJ) funded by vaccine manufacturers, including Novavax and GlaxoSmithKline within the last 3 years, but receive no personal funding from these sources.
Clinical Trial
NCT02145624
Funding Statement
This study is independent research funded by the National Institute for Health Research (NIHR) Policy Research Programme (Vaccine Evaluation Consortium Phase II, 039/0031, grant holder EM). The views expressed are those of the author(s) and not necessarily those of the NIHR, or the Department of Health and Social Care. The funder, NIHR, was not involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the MHRA, NHS Health Research Authority and City & East Research Ethics Committee (14/LO/0141)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets analysed during the current study may be available from the corresponding author on reasonable request.
Abbreviations
- aP
- acellular pertussis
- DT
- diphtheria toxoid
- ELISA
- enzyme-linked immunosorbent assays
- FHA
- filamentous haemagglutinin
- FIM
- fimbriae
- GMC
- geometric mean concentration
- GMR
- geometric mean ratio
- GSK
- GlaxoSmithKline
- Hib
- Haemophilus influenzae type b
- IgG
- immunoglobulin G
- iMAP2
- immunising Mums Against Pertussis
- IPV
- inactivated poliovirus
- IU
- International Units
- LLOD
- lower limit of detection
- Men C
- meningococcal serogroup C
- PRN
- pertactin
- PT
- pertussis toxin
- PTR
- placental transfer ratio
- SAE
- serious adverse event
- TdaP3-IPV
- low dose diphtheria toxoid, tetanus toxoid, acellular pertussis [three antigens] and inactivated polio
- TdaP5-IPV
- low dose diphtheria toxoid, tetanus toxoid, acellular pertussis [five antigens] and inactivated polio
- TT
- tetanus toxoid
- UK
- United Kingdom
- WHO
- World Health Organization
